Smith, Kimberly Y

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Margolis, D. A., Brinson, C. C., Smith, G. H. R., de Vente, J., Hagins, D. P., Eron, J. J., Griffith, S. K., Clair, M. H. S., Stevens, M. C., Williams, P. E., et al. (2015) · The Lancet Infectious Diseases

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 204

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Overton, E. T., Richmond, G., Rizzardini, G., Thalme, A., Girard, P.-M., Wong, A., Porteiro, N., Swindells, S., Reynes, J., Noe, S., et al. (2023) · Clinical Infectious Diseases

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 145

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Jaeger, H., Overton, E. T., Richmond, G., Rizzardini, G., Andrade-Villanueva, J. F., Mngqibisa, R., Hermida, A. O., Thalme, A., Belonosova, E., Ajana, F., et al. (2021) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 142